227 related articles for article (PubMed ID: 31700061)
1. Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma.
Su D; Zhang D; Jin J; Ying L; Han M; Chen K; Li B; Wu J; Xie Z; Zhang F; Lin Y; Cheng G; Li JY; Huang M; Wang J; Wang K; Zhang J; Li F; Xiong L; Futreal A; Mao W
Nat Commun; 2019 Nov; 10(1):5076. PubMed ID: 31700061
[TBL] [Abstract][Full Text] [Related]
2. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
3. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.
Qie S; Yoshida A; Parnham S; Oleinik N; Beeson GC; Beeson CC; Ogretmen B; Bass AJ; Wong KK; Rustgi AK; Diehl JA
Nat Commun; 2019 Mar; 10(1):1296. PubMed ID: 30899002
[TBL] [Abstract][Full Text] [Related]
4. [CDK4/6 inhibitors: biomarkers, mechanisms of resistance and interest of the study of the circulating tumor DNA].
Gonçalves A
Bull Cancer; 2018 Jun; 105(6):545-546. PubMed ID: 29729807
[No Abstract] [Full Text] [Related]
5. A genetic variant in CDKN2A/2B locus was associated with poor prognosis in patients with esophageal squamous cell carcinoma.
Ghobadi N; Mehramiz M; ShahidSales S; Rezaei Brojerdi A; Anvari K; Khazaei M; Rezayi M; Sadegh Khorrami M; Joudi-Mashhad M; Ramshini H; Ahmadi-Simab S; Moradi A; Hassanian SM; Ghayour-Mobarhan M; Boroushaki MT; Ferns GA; Avan A
J Cell Physiol; 2019 Apr; 234(4):5070-5076. PubMed ID: 30238987
[TBL] [Abstract][Full Text] [Related]
6. Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells.
Chen L; Pan J
Br J Pharmacol; 2017 Aug; 174(15):2427-2443. PubMed ID: 28444744
[TBL] [Abstract][Full Text] [Related]
7. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T
Mol Cancer Ther; 2019 Apr; 18(4):771-779. PubMed ID: 30837298
[TBL] [Abstract][Full Text] [Related]
8. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
Scott SC; Lee SS; Abraham J
Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
[TBL] [Abstract][Full Text] [Related]
10. An Old Story Retold: Loss of G1 Control Defines A Distinct Genomic Subtype of Esophageal Squamous Cell Carcinoma.
Wang Q; Bai J; Abliz A; Liu Y; Gong K; Li J; Shi W; Pan Y; Liu F; Lai S; Yang H; Lu C; Zhang L; Chen W; Xu R; Cai H; Ke Y; Zeng C
Genomics Proteomics Bioinformatics; 2015 Aug; 13(4):258-70. PubMed ID: 26386145
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cyclin-dependent kinases 4 and 6 in breast cancer.
Mayer EL
Clin Adv Hematol Oncol; 2015 Apr; 13(4):215-7. PubMed ID: 26352578
[No Abstract] [Full Text] [Related]
12. CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.
Zhou J; Wu Z; Wong G; Pectasides E; Nagaraja A; Stachler M; Zhang H; Chen T; Zhang H; Liu JB; Xu X; Sicinska E; Sanchez-Vega F; Rustgi AK; Diehl JA; Wong KK; Bass AJ
Nat Commun; 2017 Jan; 8():13897. PubMed ID: 28059068
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Konecny GE
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
[TBL] [Abstract][Full Text] [Related]
14. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
15. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
16. Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting.
Criscitiello C; Viale G; Curigliano G
Curr Opin Oncol; 2017 Nov; 29(6):428-433. PubMed ID: 28872469
[TBL] [Abstract][Full Text] [Related]
17. CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.
Eilers G; Czaplinski JT; Mayeda M; Bahri N; Tao D; Zhu M; Hornick JL; Lindeman NI; Sicinska E; Wagner AJ; Fletcher JA; Mariño-Enriquez A
Mol Cancer Ther; 2015 Jun; 14(6):1346-53. PubMed ID: 25852058
[TBL] [Abstract][Full Text] [Related]
18. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Laderian B; Fojo T
Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
[TBL] [Abstract][Full Text] [Related]
20. CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma.
Salvador-Barbero B; Álvarez-Fernández M; Zapatero-Solana E; El Bakkali A; Menéndez MDC; López-Casas PP; Di Domenico T; Xie T; VanArsdale T; Shields DJ; Hidalgo M; Malumbres M
Cancer Cell; 2020 Mar; 37(3):340-353.e6. PubMed ID: 32109375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]